Treatment of early diffuse systemic sclerosis skin disease

Clin Exp Rheumatol. Mar-Apr 2013;31(2 Suppl 76):166-71. Epub 2013 Jul 23.

Abstract

Diffuse systemic sclerosis carries a high morbidity and mortality. The Prospective Registry of Early Systemic Sclerosis (PRESS), a multicentre incident cohort study of patients with early diffuse cutaneous systemic sclerosis, has the goal of advancing the understanding of disease pathogenesis and identifying novel biomarkers. In this review, PRESS investigators discuss the evidence pertaining to the more commonly used treatments for early diffuse SSc skin disease including methotrexate, mycophenolate, cyclophosphamide, azathioprine, and intravenous immunoglobulin. This review highlights the unmet need for effective treatment in early diffuse SSc as well as its more rigorous study. Nonetheless, the PRESS investigators aim to decrease intra- and inter-institutional variability in prescribing in order to improve the understanding of the clinical course of early diffuse SSc skin disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Biomarkers / metabolism
  • Early Diagnosis
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Scleroderma, Diffuse / diagnosis*
  • Scleroderma, Diffuse / drug therapy*
  • Scleroderma, Diffuse / mortality

Substances

  • Biomarkers
  • Immunosuppressive Agents